Analysts’ Weekly Ratings Changes for Zimmer Biomet (ZBH)

Several analysts have recently updated their ratings and price targets for Zimmer Biomet (NYSE: ZBH):

• 2/10/2025 – Zimmer Biomet had its price target lowered by analysts at Barclays PLC from $118.00 to $112.00. They now have an “underweight” rating on the stock.
• 2/10/2025 – Zimmer Biomet had its “hold” rating reaffirmed by analysts at Truist Financial Co.. They now have a $113.00 price target on the stock, down previously from $118.00.
• 2/7/2025 – Zimmer Biomet had its price target lowered by analysts at Royal Bank of Canada from $130.00 to $125.00. They now have an “outperform” rating on the stock.
• 2/7/2025 – Zimmer Biomet had its price target lowered by analysts at Raymond James from $126.00 to $119.00. They now have an “outperform” rating on the stock.
• 2/7/2025 – Zimmer Biomet had its “market outperform” rating reaffirmed by analysts at JMP Securities. They now have a $140.00 price target on the stock.
• 2/7/2025 – Zimmer Biomet had its “hold” rating reaffirmed by analysts at Needham & Company LLC.
• 1/29/2025 – Zimmer Biomet had its “hold” rating reaffirmed by analysts at Needham & Company LLC.
• 1/23/2025 – Zimmer Biomet had its price target raised by analysts at Stifel Nicolaus from $130.00 to $138.00. They now have a “buy” rating on the stock.

Zimmer Biomet Price Performance

ZBH opened at $100.52 on Tuesday. The stock has a 50-day moving average price of $106.34 and a 200-day moving average price of $107.67. Zimmer Biomet Holdings, Inc. has a 12-month low of $97.69 and a 12-month high of $133.90. The company has a current ratio of 1.91, a quick ratio of 0.70 and a debt-to-equity ratio of 0.43. The stock has a market capitalization of $20.01 billion, a P/E ratio of 22.59, a PEG ratio of 1.83 and a beta of 1.02.

Zimmer Biomet (NYSE:ZBH) last issued its earnings results on Thursday, February 6th. The medical equipment provider reported $2.31 earnings per share for the quarter, beating the consensus estimate of $2.30 by $0.01. Zimmer Biomet had a return on equity of 12.99% and a net margin of 11.77%. During the same quarter in the previous year, the firm posted $2.20 earnings per share. Equities analysts predict that Zimmer Biomet Holdings, Inc. will post 8.25 earnings per share for the current fiscal year.

Zimmer Biomet Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Friday, January 31st. Stockholders of record on Monday, December 30th were given a $0.24 dividend. This represents a $0.96 annualized dividend and a dividend yield of 0.96%. The ex-dividend date was Monday, December 30th. Zimmer Biomet’s dividend payout ratio is currently 21.57%.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in ZBH. Stonebridge Financial Group LLC bought a new position in Zimmer Biomet during the 4th quarter valued at approximately $25,000. Dunhill Financial LLC raised its holdings in Zimmer Biomet by 1,090.0% during the third quarter. Dunhill Financial LLC now owns 238 shares of the medical equipment provider’s stock valued at $26,000 after acquiring an additional 218 shares during the period. Ashton Thomas Securities LLC bought a new stake in Zimmer Biomet during the third quarter valued at about $28,000. Brooklyn Investment Group bought a new stake in shares of Zimmer Biomet in the third quarter worth about $35,000. Finally, Accredited Wealth Management LLC bought a new stake in shares of Zimmer Biomet in the fourth quarter worth about $36,000. Institutional investors own 88.89% of the company’s stock.

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.